I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of ...

Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel ...

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, ...

Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to ...

The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off ...

Analysts have recently evaluated Arcellx and provided 12-month price targets. The average target is $107.71, accompanied by a ...

UBS analyst Ashwani Verma raised the firm’s price target on Arcellx (ACLX) to $114 from $106 and keeps a Buy rating on the shares. UBS believes ...

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Arcellx Inc (ACLX – Research Report), with a price ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports. They presently ...

--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable ...